Rigel Pharmaceuticals (RIGL) Other Gross PP&E Adjustments (2011 - 2026)

Rigel Pharmaceuticals has reported Other Gross PP&E Adjustments for 16 years, with the latest figure at -$2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Other Gross PP&E Adjustments fell 95.25% year-over-year to -$2.5 million; the trailing twelve-month figure through Mar 2026 stood at -$2.5 million (down 95.25% YoY), and the FY2025 full-year result was -$573000.0, down 635.51% from the prior year.
• Other Gross PP&E Adjustments for Q1 2026 stood at -$2.5 million, down from -$573000.0 in the prior quarter.
• The five-year high for Other Gross PP&E Adjustments was $9.7 million in Q4 2022, with the low at -$7.5 million in Q1 2022.
• Average Other Gross PP&E Adjustments over 5 years is -$961529.4, with a median of -$1.0 million recorded in 2023.
• Year-over-year, Other Gross PP&E Adjustments surged 85.03% in 2023 and sank 635.51% in 2025.
• Tracing RIGL's Other Gross PP&E Adjustments over 5 years: stood at $9.7 million in 2022, then sank by 89.64% to $1.0 million in 2023, then plunged by 89.38% to $107000.0 in 2024, then slumped by 635.51% to -$573000.0 in 2025, then slumped by 344.68% to -$2.5 million in 2026.
• The last three Other Gross PP&E Adjustments figures came in at -$2.5 million (Q1 2026), -$573000.0 (Q4 2025), and -$1.0 million (Q3 2025), per Business Quant data.

Peer Comparison